The global antibody drug conjugates market in terms of revenue was estimated to be worth $9.7 billion in 2023 and is poised to reach $19.8 billion by 2028, growing at a CAGR of 15.2% from 2023 to 2028. The Antibody Drug Conjugates (ADCs) market is a rapidly evolving sector within the biopharmaceutical industry, characterized by its innovative approach to targeted cancer therapy. ADCs combine the specificity of monoclonal antibodies with the cytotoxic power of chemotherapeutic agents, providing a potent means to attack cancer cells while minimizing damage to healthy tissues. This article delves into the size, growth, and specific aspects of the ADC market, focusing on linker types and payload types.

Key players in the antibody drug conjugates market include F. Hoffmann-La Roche Ltd (Switzerland), Daiichi Sankyo Company, Limited (Japan), Seagen Inc. (US), Gilead Sciences, Inc. (US), Takeda Pharmaceutical Company Limited (Japan), Pfizer Inc. (US), Astellas Pharma Inc (Japan), AstraZeneca (UK), ADC Therapeutics SA (Switzerland), ImmunoGen, Inc. (US), Zydus Group (India).

Download the Free Sample Report at https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=122857391

Market Size and Growth

The global ADC market has experienced substantial growth in recent years and is expected to continue expanding at a significant rate. According to market research, the ADC market was valued at approximately USD 4 billion in 2022 and is projected to reach USD 12 billion by 2028, growing at a compound annual growth rate (CAGR) of over 20% during the forecast period. This growth is driven by the increasing prevalence of cancer, advancements in ADC technology, and a growing number of ADCs in clinical trials and approvals.

Key factors contributing to market growth include:

1. Rising Cancer Incidence: The global increase in cancer cases necessitates the development of more effective and targeted therapies.
2. Technological Advancements: Innovations in linker technology, payloads, and antibody engineering enhance the efficacy and safety of ADCs.
3. Regulatory Approvals: Growing regulatory support and approvals for new ADCs boost market expansion.

Linker Types: Cleavable vs. Non-Cleavable

Linkers play a crucial role in the stability and efficacy of ADCs. They connect the antibody to the cytotoxic drug, ensuring that the payload is delivered specifically to the cancer cells. Linkers can be broadly categorized into two types: cleavable and non-cleavable.

1. Cleavable Linkers:
• Mechanism: These linkers are designed to release the cytotoxic drug upon entering the target cell's environment, often triggered by specific conditions such as acidic pH or the presence of particular enzymes.
• Advantages: Cleavable linkers enable precise drug release within the cancer cell, maximizing the payload's therapeutic effect while reducing systemic toxicity.
• Examples: Examples of cleavable linkers include valine-citrulline (Val-Cit) and acid-labile linkers.
2. Non-Cleavable Linkers:
• Mechanism: These linkers remain intact until the ADC is internalized and degraded within the cancer cell, ensuring that the payload remains attached to the antibody until cellular processing occurs.
• Advantages: Non-cleavable linkers provide greater stability in the bloodstream, reducing premature drug release and off-target effects.
• Examples: Thioether linkers are a common type of non-cleavable linker used in ADCs.

Payload Types: Calicheamicin and MMAE

The payload, or cytotoxic agent, is the component of the ADC responsible for killing cancer cells. Two prominent types of payloads used in ADCs are Calicheamicin and Monomethyl Auristatin E (MMAE).

1. Calicheamicin:
• Origin: Derived from the bacterium Micromonospora echinospora, Calicheamicin is a potent DNA-damaging agent.
• Mechanism: It induces double-strand breaks in DNA, leading to cell death.
• Applications: Calicheamicin-based ADCs are effective against hematological malignancies. An example is gemtuzumab ozogamicin (Mylotarg), used for acute myeloid leukemia.
2. Monomethyl Auristatin E (MMAE):
• Origin: MMAE is a synthetic derivative of dolastatin 10, a natural product isolated from sea hare.
• Mechanism: It inhibits tubulin polymerization, disrupting the microtubule network and causing cell cycle arrest and apoptosis.
• Applications: MMAE is used in ADCs targeting solid tumors and hematologic cancers. Brentuximab vedotin (Adcetris) is an example used to treat Hodgkin lymphoma and systemic anaplastic large cell lymphoma.

Direct Purchase at https://www.marketsandmarkets.com/Purchase/purchase_reportNew.asp?id=122857391

The Antibody Drug Conjugates market is poised for remarkable growth, driven by the increasing need for targeted cancer therapies and advancements in ADC technology. The choice of linker and payload types plays a critical role in the design and efficacy of ADCs, with cleavable and non-cleavable linkers offering distinct advantages, and payloads like Calicheamicin and MMAE providing powerful anti-cancer effects. As research and development continue, the ADC market is expected to witness further innovations, offering new hope for patients with challenging cancers.